Orthocell Ltd

About Orthocell Ltd

Orthocell is a regenerative medicine company focused on developing world-leading products to unlock the human body's healing potential, restoring mobility, function, and performance.

Products & Services

Striate+™:A product focused on supporting the body's repair mechanisms.

Remplir™:A flagship nerve repair product, recently FDA cleared, with successful commercialization in the US market.

OrthoACI™:A regenerative medicine therapy for complex injuries.

Tendon:A product aimed at tendon repair and regeneration.

Specialties

Regenerative Medicine Nerve Repair Tendon Repair Collagen Medical Devices

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Options Issuance T: - FT: Options Issuance	A: 2000000 MR: - FA: 2,000,000 unquoted options FAN: 2000000	D: 2025-09-01 FD: 2025-09-01	-

Options Issuance Latest

2025-09-01

$2.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Van Der Wielen

Chairman

P

Paul Anderson

Co-Founder and Managing Director

R

Ravi I. Thadhani

Lead Independent Director

F

Fiona Wood

Non-Executive Director

M

Michael McNulty

Non-Executive Director

M

Ming Hao Zheng

Co-Founder and Chief Scientific Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

Orthocell Ltd Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised